BRAF and melanoma: Although the administration of a BRAF inhibitor (such as vemurafenib) improves patient survival, approximately 70% of patients acquire drug resistance within 6 months [36, 37]; therefore, overcoming drug resistance is a challenge for melanoma-targeting therapeutic treatments.